REGENXBIO (RGNX) Hisse Özeti
Klinik aşamada bir biyoteknoloji şirketi olan REGENXBIO Inc., Amerika Birleşik Devletleri'nde genetik kusurları olan hücrelere işlevsel genler sağlayan gen terapileri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
RGNX Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
REGENXBIO Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$11.07 |
| 52 Haftanın En Yüksek Seviyesi | US$16.19 |
| 52 Haftanın En Düşük Seviyesi | US$5.46 |
| Beta | 0.94 |
| 1 Aylık Değişim | 11.93% |
| 3 Aylık Değişim | 85.43% |
| 1 Yıllık Değişim | 37.86% |
| 3 Yıllık Değişim | -38.53% |
| 5 Yıllık Değişim | -65.00% |
| Halka arzdan bu yana değişim | -63.65% |
Son Haberler & Güncellemeler
Seeking Alpha • Aug 11
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
Summary Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months. Valuation embeds partial pipeline success but not full de-risking; execution on upcoming clinical milestones is key for re-rating potential. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 08
RGNX: Hunter Syndrome Refiling Plans Will Drive Future Upside Potential
Analysts have reduced the updated fair value estimate for REGENXBIO stock to about $45.54 from roughly $51.93. The change reflects a higher discount rate and mixed price target changes across the Street, which weigh regulatory uncertainty against potential upside from the gene therapy pipeline.Recent updates
Seeking Alpha • Aug 11
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
Summary Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months. Valuation embeds partial pipeline success but not full de-risking; execution on upcoming clinical milestones is key for re-rating potential. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 08
RGNX: Hunter Syndrome Refiling Plans Will Drive Future Upside Potential
Analysts have reduced the updated fair value estimate for REGENXBIO stock to about $45.54 from roughly $51.93. The change reflects a higher discount rate and mixed price target changes across the Street, which weigh regulatory uncertainty against potential upside from the gene therapy pipeline.
Anlatı Güncellemesi • Jun 15
RGNX: Future Duchenne Regulatory Outcomes Will Test Gene Therapy Bullish Thesis
Narrative Update on REGENXBIO The analyst price target for REGENXBIO in this framework moves from $12.00 to $10.00 as analysts factor in recent target cuts tied to a higher projected share count and continued regulatory uncertainty around RGX-202 in Duchenne muscular dystrophy. At the same time, they acknowledge encouraging functional data and a higher assumed profit margin.
Anlatı Güncellemesi • Jun 01
RGNX: AFFINITY DUCHENNE Data Will Shape Future Regulatory And Share Price Upside
Analysts have trimmed the implied fair value on REGENXBIO stock from about $29.75 to roughly $24.18. This reflects a cluster of lower Street price targets in the $12 to $42 range as they factor in a higher discount rate, updated views on RGX-202 regulatory uncertainty, and revised expectations for revenue growth, profit margins, and future P/E.Anlatı Güncellemesi • Apr 26
RGNX: Future Gene Therapy Milestones Will Test Regulatory Risk And Support Bullish Reassessment
REGENXBIO's consensus analyst price target has been revised lower, with cuts ranging from about $1 to $12 as analysts factor in updated clinical timelines, recent FDA commentary around RGX-121 and the approach to rare disease, as well as upcoming pivotal readouts for key gene therapy programs. Analyst Commentary Recent research updates show that while several firms still carry positive ratings on REGENXBIO, they have been trimming price targets and highlighting a more cautious setup around regulatory risk, clinical execution, and timelines for key programs.Anlatı Güncellemesi • Apr 11
RGNX: Future Pivotal Gene Therapy Readouts Will Drive Bullish Reassessment
Analysts have nudged their average price target for REGENXBIO slightly lower to reflect recent target cuts across firms, while still highlighting upcoming regulatory updates and pivotal readouts in Duchenne muscular dystrophy and wet age related macular degeneration as key drivers for their updated views. Analyst Commentary Recent research updates show that while upcoming data and regulatory milestones remain central to the REGENXBIO story, several price targets have been adjusted lower following the latest quarterly results and clinical updates.Anlatı Güncellemesi • Mar 28
RGNX: Future Gene Therapy Milestones Will Drive Reassessment Despite Regulatory Uncertainty
Analysts have nudged their blended price target for REGENXBIO modestly lower by a few dollars to reflect recent reductions in firm level targets, while still pointing to upcoming regulatory updates and pivotal readouts across programs like RGX-202 and ABBV-RGX-314 as key factors in their outlook. Analyst Commentary Street research around REGENXBIO has tilted more cautious in recent weeks, with several price targets adjusted lower following the latest quarterly update, recent regulatory news and evolving views on the company’s gene therapy portfolio.Anlatı Güncellemesi • Mar 12
RGNX: Future Gene Therapy Readouts Will Drive Reassessment Despite Regulatory Setbacks
Analysts have trimmed their average price targets on REGENXBIO, with cuts such as $32 to $30, $45 to $42 and $18 to $17. These changes reflect updated assumptions for slightly lower revenue growth and profit margins, partly offset by a modestly lower discount rate and a higher future P/E multiple.Anlatı Güncellemesi • Feb 26
RGNX: Regulatory Resolution And Gene Therapy Data Will Drive Reassessment
Analysts have trimmed their price targets on REGENXBIO by up to $12, reflecting updated views on RGX-121 related regulatory uncertainty and revised assumptions for the discount rate, revenue growth, profit margin and future P/E, while the central fair value estimate remains at $12.00. Analyst Commentary Recent research updates around REGENXBIO have centered on RGX-121 and the regulatory commentary that investors are trying to interpret.Anlatı Güncellemesi • Feb 11
RGNX: Clinical Hold Setbacks Will Refocus Attention On Upcoming Pivotal Data
Analysts have trimmed their fair value estimate for REGENXBIO to $12.00 from $14.00, citing a reset in price targets across the Street following clinical updates. The revised estimate still reflects higher modeled revenue growth and a lower future P/E multiple in their assumptions.Analiz Makalesi • Feb 06
REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Jan 29
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Dec 23
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 27% gain in the last month alone. The...Analiz Makalesi • Oct 09
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29%
REGENXBIO Inc. ( NASDAQ:RGNX ) shares have continued their recent momentum with a 29% gain in the last month alone...Analiz Makalesi • Oct 03
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Aug 12
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel
NasdaqGS:RGNX 1 Year Share Price vs Fair Value Explore REGENXBIO's Fair Values from the Community and select yours With...Anlatı Güncellemesi • Aug 08
Gene Therapy Breakthroughs Will Unlock Expanding Future Markets
Analysts have revised REGENXBIO’s price target downward to $29.75, reflecting heightened sector scrutiny after competitor safety issues but maintaining confidence in RGX-202’s differentiated immune suppression strategy and clinical outlook. Analyst Commentary Safety issues with a competitor's product (Sarepta's Elevidys) have renewed focus on immune prophylaxis, highlighting Regenxbio's proactive approach to immune suppression with RGX-202.Analiz Makalesi • May 15
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for REGENXBIO Inc. ( NASDAQ:RGNX ), which a week ago released some disappointing...Analiz Makalesi • May 01
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth
REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders would be excited to see that the share price has had a great month, posting...Analiz Makalesi • Apr 24
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Yeni Anlatı • Mar 30
FDA Approval And Nippon Shinyaku Partnership Will Advance Pipeline
Strategic partnerships and FDA approvals drive potential revenue growth through new market penetrations and milestone payments.Seeking Alpha • Mar 26
5 Reasons To Buy Regenxbio Right Now
Summary Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis. Technically speaking, the stock is shifting from bearish to bullish, with significant upside potential and positive price target trends from multiple analysts. RGNX is a prime buyout candidate, with AbbVie as a likely bidder, supported by several other potential suitors in the biotech and pharma sectors that are active/interested in Gene Therapy. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 04
The Market Doesn't Like What It Sees From REGENXBIO Inc.'s (NASDAQ:RGNX) Revenues Yet As Shares Tumble 27%
To the annoyance of some shareholders, REGENXBIO Inc. ( NASDAQ:RGNX ) shares are down a considerable 27% in the last...Seeking Alpha • Jan 15
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again
Summary Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku. Despite historical underperformance, I remain hopeful, banking on the durability of their wet AMD treatment and will continue buying at dips, giving RGNX stock two more years. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive
Unfortunately for some shareholders, the REGENXBIO Inc. ( NASDAQ:RGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 31
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Summary Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030. RGX-202 for the treatment of patients with DMD and ABBV-RGX-314 for treatment of patients with diabetic retinopathy are other programs in pipeline; Late-stage studies starting Q4 of 2024 and 1st half 2025 respectively. Read the full article on Seeking AlphaAnaliz Makalesi • Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Aug 06
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Summary Regenxbio Inc.'s rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected in Q3 of 2024. Additional results from the phase 1/2/3 CAMPSIITE study, using RGX-121 for the treatment of patients with MPS II, expected in the 2nd half of 2024. Initiation of a pivotal study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q4 of 2024. Subretinal delivery of ABBV-RGX-314 for the treatment of patients with Wet-AMD is ongoing; Two studies being done are ATMOSPHERE and ASCENT and regulatory submissions U.S. And EU on track for 1st half of 2026. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that REGENXBIO Inc. ( NASDAQ:RGNX ) filed its quarterly result this time last week. The...Hissedar Getirileri
| RGNX | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 3.9% | 1.8% | -0.3% |
| 1Y | 37.9% | 40.4% | 19.9% |
Getiri vs. Endüstri: RGNX geçen yıl boyunca % 40.4 oranında getiri sağlayan US Biotechs sektörüyle eşleşti.
Getiri vs Piyasa: RGNX geçen yıl % 19.9 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: RGNX hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: RGNX 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2008 | 371 | Curran Simpson | www.regenxbio.com |
Klinik aşamada bir biyoteknoloji şirketi olan REGENXBIO Inc., Amerika Birleşik Devletleri'nde genetik kusurları olan hücrelere fonksiyonel genler sağlayan gen terapileri sunmaktadır. Gen terapisi ürün adayları, tescilli bir adeno-ilişkili virüs gen dağıtım platformu olan NAV Teknoloji Platformuna dayanmaktadır. Şirketin boru hattındaki ürünleri arasında yaşa bağlı makula dejenerasyonu, diyabetik retinopati ve diğer kronik retina hastalıklarının tedavisi için ABBV-RGX-314; Duchenne musküler distrofisinin tedavisi için RGX-202 ve mukopolisakkaridoz tip II tedavisi için RGX-121 bulunmaktadır.
REGENXBIO Inc. Temel Bilgiler Özeti
| RGNX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$747.93m |
| Kazançlar(TTM) | -US$196.43m |
| Gelir(TTM) | US$174.48m |
4.2x
P/S Oranı-3.7x
F/K OranıRGNX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| RGNX gelir tablosu (TTM) | |
|---|---|
| Gelir | US$174.48m |
| Gelir Maliyeti | US$252.91m |
| Brüt Kâr | -US$78.42m |
| Diğer Giderler | US$118.01m |
| Kazançlar | -US$196.43m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -2.98 |
| Brüt Marj | -44.95% |
| Net Kâr Marjı | -112.58% |
| Borç/Özkaynak Oranı | 252.9% |
RGNX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/18 12:53 |
| Gün Sonu Hisse Fiyatı | 2026/08/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
REGENXBIO Inc. 24 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |